47 genetic-algorithm-computer-"Prof" Fellowship positions at University of Birmingham
Sort by
Refine Your Search
-
the origin of seed gene networks”. This project aims to use reverse genetics, cross-species complementation and single cell next-generation sequencing approaches to investigate how the gene networks
-
administration and communication activities. The recruit will work with Dr Peter Hopcroft and Dr Thomas Pugh and Prof. Vincent Gauci. Role Summary Work within the DefMet interdisciplinary project team. Investigate
-
development of future proposals for funding, into AI for renewable energy. You will consider ways in which the integration of machine learning algorithms might support the wider integration of, and uptake
-
cytoplasmic lysyl hydroxylase that modifies a translation factor GTPase (Nature Chem Bio 2018; Genet Med 2023; Structure 2024; Cell Mol Life Sci 2021). Here in this highly competitive BBSRC-funded project, you
-
initiative improving outcomes in diabetes emergencies PCOS SEVa – a national programme addressing variation in the quality of care for polycystic ovary syndrome (PCOS) Role Summary Work within specified
-
at the University of Birmingham is pleased to offer a Part-Time Research Fellow post funded through the NIHR DEMCOMM Fellowship Programme. This post supports a motivated qualitative researcher to contribute
-
contribute to the creation of knowledge by undertaking a specified range of activities within an established research programme and/or specific research project. Our international group of highly motivated and
-
to broader management/administration processes Contribute to the planning and organising of the research programme and/or specific research project Co-ordinate own work with others to avoid conflict
-
Contribute to the planning and organising of the research programme and/or specific research project Co-ordinate own work with others to avoid conflict or duplication of effort Knowledge of the protected
-
(HPB). The medical oncology grouping sees close to 550 new cases of these cancers a year. There is a large active clinical trials programme that spans phase 1 to phase 3. These patients have a poor